PL2524700T3 - Szczepionka z glikoproteiną mucynową (muc-1) do leczenia raka gruczołu krokowego - Google Patents

Szczepionka z glikoproteiną mucynową (muc-1) do leczenia raka gruczołu krokowego

Info

Publication number: PL2524700T3
Authority: PL; Poland
Prior art keywords: muc; vaccine; treatment; prostate cancer; mucinous glycoprotein
Prior art date: 2004-04-01

Application number

PL11196228T

Other languages

English (en)

Inventor

Michael Longenecker

Original Assignee

Oncothyreon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2005-04-01

Publication date

2016-04-29

2005-04-01 Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc

2016-04-29 Publication of PL2524700T3 publication Critical patent/PL2524700T3/pl

Links

102000003886 Glycoproteins Human genes 0.000 title 1
108090000288 Glycoproteins Proteins 0.000 title 1
101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
206010060862 Prostate cancer Diseases 0.000 title 1
208000000236 Prostatic Neoplasms Diseases 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Marine Sciences & Fisheries (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL11196228T 2004-04-01 2005-04-01 Szczepionka z glikoproteiną mucynową (muc-1) do leczenia raka gruczołu krokowego PL2524700T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US55813904P	2004-04-01	2004-04-01
US57680404P	2004-06-04	2004-06-04
EP05769609.8A EP1737485B1 (en)	2004-04-01	2005-04-01	Mucinous glycoprotein (muc-1) vaccine
EP11196228.8A EP2524700B1 (en)	2004-04-01	2005-04-01	Mucinous glycoprotein (muc-1) vaccine for the treatment of prostate cancer

Publications (1)

Publication Number	Publication Date
PL2524700T3 true PL2524700T3 (pl)	2016-04-29

Family

ID=35428714

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL05769609T PL1737485T3 (pl)	2004-04-01	2005-04-01	Szczepionka glikoproteiny mucynowej (muc-1)
PL11196228T PL2524700T3 (pl)	2004-04-01	2005-04-01	Szczepionka z glikoproteiną mucynową (muc-1) do leczenia raka gruczołu krokowego

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL05769609T PL1737485T3 (pl)	2004-04-01	2005-04-01	Szczepionka glikoproteiny mucynowej (muc-1)

Country Status (15)

Country	Link
US (2)	US9173929B2 (pl)
EP (2)	EP2524700B1 (pl)
JP (3)	JP5590768B2 (pl)
CN (2)	CN1997388B (pl)
AR (1)	AR051350A1 (pl)
AU (1)	AU2005244675B2 (pl)
BR (1)	BRPI0509552A (pl)
CA (1)	CA2562990A1 (pl)
DK (2)	DK1737485T3 (pl)
ES (2)	ES2478006T3 (pl)
HU (1)	HUE027378T2 (pl)
PL (2)	PL1737485T3 (pl)
PT (2)	PT1737485E (pl)
TW (2)	TW201204410A (pl)
WO (1)	WO2005112546A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004533421A (ja)	2001-03-27	2004-11-04	バイオミラ，インコーポレイテッド	Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US20060069238A1 (en) *	2002-04-15	2006-03-30	Biomira, Inc.	Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en)	2004-04-01	2012-02-01	Oncothyreon Inc	Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) *	2005-06-28	2013-12-11	オンコセリオンインコーポレイテッド	ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
AU2012268892B2 (en) *	2005-06-28	2016-05-26	Oncothyreon Inc.	Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
US20120039984A1 (en)	2008-07-03	2012-02-16	University Of Georgia Research Foundation, Inc.	Glycopeptide and uses thereof
CN102256595A (zh) *	2008-12-17	2011-11-23	肿瘤防护公司	制备小粒径脂质体的方法
WO2011054359A2 (en) *	2009-11-06	2011-05-12	University Of Copenhagen	Method for early detection of cancer
EP2560989B1 (en)	2010-04-19	2017-03-22	Sumitomo Bakelite Co., Ltd.	Cancer-related glycopeptide epitopes, antibodies and methods of use
CN105193724A (zh) *	2011-02-24	2015-12-30	肿瘤防护公司	含有佐剂的以muc1 为基础的糖脂肽疫苗
PT2723363T (pt)	2011-06-24	2018-11-08	Nono Inc	Terapia de combinação para isquemia
DE102011085695A1 (de) *	2011-11-03	2013-05-08	Jörg Pohl	Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9241970B2 (en) *	2011-12-13	2016-01-26	Nono Inc.	Therapy for subarachnoid hemorrhage and ischemia
CN105283199A (zh)	2013-05-14	2016-01-27	默克专利股份公司	通过muc-1脂肽接种治疗肺癌的方法
CN105517566A (zh) *	2013-08-21	2016-04-20	库瑞瓦格股份公司	用于治疗前列腺癌的组合物和疫苗
WO2015058831A1 (en)	2013-10-25	2015-04-30	Merck Patent Gmbh	Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110393797A (zh) *	2019-05-27	2019-11-01	南开大学	基于糖脂佐剂的糖肽疫苗的制备方法与应用
US11878057B2 (en) *	2020-12-11	2024-01-23	Trustees Of Boston University	Immunomodulatory lipopolysaccharide compositions
WO2026011417A1 (en) *	2024-07-12	2026-01-15	The Hong Kong University Of Science And Technology	Compositions and methods involving artificial poly (a) sequences

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en)	1981-01-09	1991-05-28	New York Blood Center, Inc.	Fatty acid carriers for synthetic peptides
ZA831547B (en)	1982-03-15	1984-10-31	New York Blood Center Inc	Fatty acid carriers for synthetic vaccines
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US6090406A (en)	1984-04-12	2000-07-18	The Liposome Company, Inc.	Potentiation of immune responses with liposomal adjuvants
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
DE3683688D1 (de)	1985-04-19	1992-03-12	Wistar Inst	Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
IT1213029B (it)	1986-01-30	1989-12-07	Bracco Ind Chimica Spa	Chelati di ioni metallici paramagnetici.
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4868155A (en)	1987-10-05	1989-09-19	Merck & Co., Inc.	Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
DK0478715T3 (da)	1989-06-23	1996-08-05	Liposome Co Inc	Målrettede liposomer og fremgangsmåder til liposom-protein-kobling
FR2670787B1 (fr)	1990-12-18	1995-06-23	Pasteur Institut	Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en)	1990-12-18	1999-11-30	Institut Pasteur De Lille	Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5871746A (en)	1990-12-18	1999-02-16	Institut National De La Sainte Et De La Recherche Medicale (Inserm)	Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
ES2044781B1 (es)	1992-04-14	1994-10-01	Menarini Lab	Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en)	1992-05-01	1993-11-11	The Rockfeller University	Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en)	1993-07-30	1998-04-28	University Of Pittsburgh University Patent Committee Policy And Procedures	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en)	1994-04-12	1995-10-30	Biomira Inc.	Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en)	1994-05-02	1995-11-09	Ting Chi Wong	Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en)	1995-06-07	1996-12-19	National Jewish Center For Immunology And Respiratory Medicine	Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en)	1995-09-27	1995-10-26	Austin Research Institute, The	Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en)	1996-02-09	1998-11-24	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU734253B2 (en)	1996-03-20	2001-06-07	Sloan-Kettering Institute For Cancer Research	Conjugated mucin peptide vaccines
ATE273320T1 (de)	1996-04-11	2004-08-15	Univ British Columbia	Fusogene liposomen
US5910306A (en)	1996-11-14	1999-06-08	The United States Of America As Represented By The Secretary Of The Army	Transdermal delivery system for antigen
JP4480800B2 (ja)	1997-05-08	2010-06-16	オンコシリオン・インコーポレイテッド	活性化ｔ細胞および抗原パルス標識した抗原提示細胞を生成する方法
JPH11139961A (ja)	1997-11-06	1999-05-25	Taisho Pharmaceut Co Ltd	リポソームの製造方法
EP1045688A1 (en)	1998-01-16	2000-10-25	Biomira Usa Inc.	Lipomatrix preparation
FR2774687B1 (fr)	1998-02-06	2002-03-22	Inst Nat Sante Rech Med	Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr)	1998-04-07	2003-10-24	Inst Nat Sante Rech Med	Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US6104536A (en)	1998-09-18	2000-08-15	3M Innovative Properties Company	High efficiency polarization converter including input and output lenslet arrays
ATE397488T1 (de)	1998-11-13	2008-06-15	Heriot William A	Vorrichtung zur herstellung von liposomen
US20020051813A1 (en) *	1999-01-15	2002-05-02	Lawrence Boni	Lipomatrix preparation
US7147850B2 (en)	1999-08-18	2006-12-12	Altarex Medical Corp.	Therapeutic binding agents against MUC-1 antigen and methods for their use
DE60018761T2 (de)	1999-08-18	2006-02-02	Altarex Medical Corp., Edmonton	Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
JP2003510094A (ja)	1999-09-08	2003-03-18	トランジェーヌ、ソシエテ、アノニム	Ｍｕｃ−１由来のペプチド
AU780577B2 (en)	1999-11-15	2005-04-07	Oncothyreon Inc.	Synthetic Lipid-A analogs and uses thereof
WO2001070265A2 (en)	2000-03-24	2001-09-27	Biomira, Inc.	Lipopeptide adjuvants
EP1182210A1 (en)	2000-08-17	2002-02-27	BASTERT, Gunter, Prof.Dr.med.Dr.h.c.	Epitopes of tumor-associated MUC1 antigen
EP1203614A1 (de)	2000-11-03	2002-05-08	Polymun Scientific Immunbiologische Forschung GmbH	Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
AU1999802A (en) *	2000-12-01	2002-06-11	Lawrence Boni	Preparation of large liposomes by infusion into peg
JP2004533421A (ja)	2001-03-27	2004-11-04	バイオミラ，インコーポレイテッド	Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
EP2263465A1 (en) *	2001-07-06	2010-12-22	Sloan-Kettering Institute for Cancer Research	Polyvalent conjugate vaccine for cancer
JP3760467B2 (ja)	2002-04-09	2006-03-29	ソニー株式会社	コンテンツ再生装置および方法、記録媒体、並びにプログラム
US20060069238A1 (en)	2002-04-15	2006-03-30	Biomira, Inc.	Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de)	2002-05-09	2010-03-15	Oncothyreon Inc	Lipid-a- und andere kohlenhydrat-liganden-analoga
US20030235610A1 (en)	2002-06-21	2003-12-25	Piedmont Pharmaceuticals, Llc	Liposomes containing biologically active compounds
US7718189B2 (en)	2002-10-29	2010-05-18	Transave, Inc.	Sustained release of antiinfectives
US7595195B2 (en)	2003-02-11	2009-09-29	The Regents Of The University Of California	Microfluidic devices for controlled viscous shearing and formation of amphiphilic vesicles
US9198645B2 (en)	2003-11-26	2015-12-01	The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology	Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en)	2004-04-01	2012-02-01	Oncothyreon Inc	Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja)	2005-06-28	2013-12-11	オンコセリオンインコーポレイテッド	ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
CN103989633A (zh)	2005-07-27	2014-08-20	普洛体维生物治疗公司	制造脂质体的系统和方法
JP5126874B2 (ja)	2007-05-21	2013-01-23	国立大学法人神戸大学	リポソーム製剤の製造方法
CN102256595A (zh)	2008-12-17	2011-11-23	肿瘤防护公司	制备小粒径脂质体的方法

2005
- 2005-03-31 TW TW100134756A patent/TW201204410A/zh unknown
- 2005-03-31 TW TW094110256A patent/TWI395591B/zh not_active IP Right Cessation
- 2005-04-01 US US10/594,992 patent/US9173929B2/en not_active Expired - Fee Related
- 2005-04-01 ES ES05769609.8T patent/ES2478006T3/es not_active Expired - Lifetime
- 2005-04-01 ES ES11196228.8T patent/ES2560808T3/es not_active Expired - Lifetime
- 2005-04-01 EP EP11196228.8A patent/EP2524700B1/en not_active Expired - Lifetime
- 2005-04-01 PT PT57696098T patent/PT1737485E/pt unknown
- 2005-04-01 CN CN200580017899.7A patent/CN1997388B/zh not_active Expired - Fee Related
- 2005-04-01 JP JP2007505675A patent/JP5590768B2/ja not_active Expired - Fee Related
- 2005-04-01 PL PL05769609T patent/PL1737485T3/pl unknown
- 2005-04-01 EP EP05769609.8A patent/EP1737485B1/en not_active Expired - Lifetime
- 2005-04-01 AU AU2005244675A patent/AU2005244675B2/en not_active Ceased
- 2005-04-01 CA CA002562990A patent/CA2562990A1/en not_active Abandoned
- 2005-04-01 HU HUE11196228A patent/HUE027378T2/en unknown
- 2005-04-01 BR BRPI0509552-2A patent/BRPI0509552A/pt not_active IP Right Cessation
- 2005-04-01 DK DK05769609.8T patent/DK1737485T3/da active
- 2005-04-01 PL PL11196228T patent/PL2524700T3/pl unknown
- 2005-04-01 PT PT111962288T patent/PT2524700E/pt unknown
- 2005-04-01 WO PCT/IB2005/002479 patent/WO2005112546A2/en not_active Ceased
- 2005-04-01 DK DK11196228.8T patent/DK2524700T3/en active
- 2005-04-01 AR ARP050101311A patent/AR051350A1/es not_active Application Discontinuation
- 2005-04-01 CN CN201410053925.2A patent/CN103933556A/zh active Pending
2011
- 2011-11-04 JP JP2011242039A patent/JP5868125B2/ja not_active Expired - Fee Related
2014
- 2014-05-15 JP JP2014101006A patent/JP2014177479A/ja active Pending
2015
- 2015-09-25 US US14/866,420 patent/US20160082093A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1737485E (pt)	2014-08-22
JP2014177479A (ja)	2014-09-25
JP5590768B2 (ja)	2014-09-17
HUE027378T2 (en)	2016-10-28
JP2012092105A (ja)	2012-05-17
EP2524700B1 (en)	2015-10-28
DK2524700T3 (en)	2016-02-01
JP5868125B2 (ja)	2016-02-24
HK1109574A1 (en)	2008-06-13
WO2005112546A2 (en)	2005-12-01
WO2005112546A3 (en)	2006-05-04
JP2007530663A (ja)	2007-11-01
CN1997388A (zh)	2007-07-11
TW200538147A (en)	2005-12-01
PT2524700E (pt)	2016-02-29
TWI395591B (zh)	2013-05-11
CA2562990A1 (en)	2005-12-01
EP1737485A4 (en)	2008-09-03
BRPI0509552A (pt)	2007-09-18
AU2005244675B2 (en)	2011-07-21
CN103933556A (zh)	2014-07-23
CN1997388B (zh)	2014-03-26
ES2560808T3 (es)	2016-02-22
PL1737485T3 (pl)	2014-10-31
ES2478006T3 (es)	2014-07-18
AR051350A1 (es)	2007-01-10
EP1737485B1 (en)	2014-05-07
TW201204410A (en)	2012-02-01
EP2524700A1 (en)	2012-11-21
EP1737485A2 (en)	2007-01-03
DK1737485T3 (da)	2014-08-04
US9173929B2 (en)	2015-11-03
US20080131495A1 (en)	2008-06-05
US20160082093A1 (en)	2016-03-24
AU2005244675A1 (en)	2005-12-01

Publication	Publication Date	Title
PT2524700E (pt)	2016-02-29	Vacina de glicoproteína mucinosa (muc-1)
HUS1900030I1 (hu)	2020-04-28	Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére
IL227841A0 (en)	2013-09-30	Dihydropyridinones for the treatment of cancer
IL210401A0 (en)	2011-03-31	Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
PL1896051T3 (pl)	2015-04-30	Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
PT1830847E (pt)	2015-02-05	Tratamento para o cancro
GB0428187D0 (en)	2005-01-26	Cancer treatment
GB0404675D0 (en)	2004-04-07	Cancer treatment
GB0410379D0 (en)	2004-06-16	Treatment of cancer
PL1618130T3 (pl)	2013-08-30	Szczepionka terapeutyczna przeciw nowotworom
GB0423273D0 (en)	2004-11-24	Treatment of cancer
GB0414885D0 (en)	2004-08-04	Cancer therapy
GB0324482D0 (en)	2003-11-19	Methods for the treatment of cancer
GB0421734D0 (en)	2004-11-03	Treatment of cancer
GB0420845D0 (en)	2004-10-20	Treatment of cancer
GB0422225D0 (en)	2004-11-03	Treatment of cancer
IL180460A0 (en)	2007-06-03	Treatment of cancer
TWI340648B (en)	2011-04-21	Dna cancer vaccines